Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -370.28
- Piotroski Score 4.00
- Grade Neutral
- Symbol (TCRT)
- Company Alaunos Therapeutics, Inc.
- Price $2.14
- Changes Percentage (1.9%)
- Change $0.04
- Day Low $2.10
- Day High $2.29
- Year High $33.00
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$32.48
- Trailing P/E Ratio -0.03
- Forward P/E Ratio -0.03
- P/E Growth -0.03
- Net Income $-35,140,000
Income Statement
Quarterly
Annual
Latest News of TCRT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
TCRT Stock Price | Alaunos Therapeutics Inc. Stock Quote (U.S.: Nasdaq) | MarketWatch
Alaunos Therapeutics, Inc. is a biopharmaceutical company specializing in oncology-focused cell therapy. They develop TCR-T cell therapies to treat various solid tumors in cancer patients. Founded in ...
By MarketWatch | 1 month ago
